The Zacks Analyst Blog Highlights: Isis Pharma, PTC Therapeutics, Ophthotech, Amgen and Biogen - KHGI-TV/KWNB-TV/KHGI-CD-Grand Island, Kearney, Hastings

The Zacks Analyst Blog Highlights: Isis Pharma, PTC Therapeutics, Ophthotech, Amgen and Biogen

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Zacks Investment Research, Inc.

CHICAGO, May 29, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Isis Pharma (Nasdaq:ISIS-Free Report), PTC Therapeutics (Nasdaq:PTCT-Free Report), Ophthotech (Nasdaq:OPHT-Free Report), Amgen (Nasdaq:AMGN-Free Report) andBiogen (Nasdaq:BIIB-Free Report).

Zacks Investment Research, Inc., www.zacks.com

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

Major biotech stories last week included Isis Pharma's (Nasdaq:ISIS-Free Report) mid-stage data on its experimental anti-coagulant, a positive opinion for PTC Therapeutics (Nasdaq:PTCT-Free Report) and a billion dollar plus deal for Ophthotech (Nasdaq:OPHT-Free Report). Other updates included the usual regulatory and pipeline events.

Isis's Pipeline Success Story Continues: Isis' shares were up 7.54% on positive top-line data from a mid-stage study on its experimental anti-coagulant, ISIS-FXIRx. Two doses of ISIS-FXIRx (200mg, 300mg) were compared to Sanofi's Lovenox. Patients in the 300mg group experienced a seven-fold lower incidence in venous thrombolic events (VTE) compared to patients on Lovenox.

ISIS-FXIRx works by inhibiting the production of Factor XI -- a coagulation factor that plays a key role in the formation of blood clots. High levels of Factor XI increase the risk of thrombosis, which could lead to heart attacks and strokes. Moreover, high levels of Factor XI increase the risk of venous thrombosis, a common problem after surgery, especially major orthopedic procedures like knee or hip replacement.

The phase II data on ISIS-FXIRx looks good -- Isis could very well strike a lucrative partnership deal based on these results. The lower incidence of bleeding is important as bleeding is a major concern associated with the use of anti-coagulants and could prove to be fatal. So a lower bleeding rate could provide ISIS-FXIRx with an edge over existing anti-coagulants. The multi-billion dollar anti-coagulant market represents huge commercial potential.

CHMP Opinion Boosts PTC Therapeutics: PTC Therapeutics soared 30.7% on a positive opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding its experimental Duchenne muscular dystrophy (DMD) treatment, Translarna. What makes this news significant is that earlier this year, the CHMP had issued a negative opinion for this very same treatment.

The company is seeking conditional marketing approval for the treatment of nonsense mutation DMD (nmDMD). So with the CHMP now adopting a positive stand, Translarna could well gain conditional approval in the EU within three months. This is great news for PTC as developing DMD drugs is not easy.

But this doesn't mean that PTC does not need to conduct phase III studies. In fact, the company expects to finish enrolling patients in an ongoing phase III study by mid-14 – positive results from this study would help the company gain full approval in the EU and the U.S.

Sarepta, another company with a DMD candidate, eteplirsen, in its pipeline, saw its shares inching up (about 4.6%) on the positive PTC development. Sarepta is looking to file for FDA approval by year end.

Billion Dollar Plus Deal for Ophthotech: Ophthotech signed a deal that could see it receiving more than $1 billion plus royalties from Novartis. Novartis gained exclusive ex-U.S. commercialization rights to Ophthotech's lead pipeline candidate, Fovista. Fovista is the most advanced anti-PDGF agent in development for the treatment of wet age-related macular degeneration.

The deal looks good for Ophthotech, which stands to gain a lot financially. Plus, Novartis has lots of experience in the eye care market given the strong presence of Alcon (a Novartis company). Ophthotech also managed to retain rights in the U.S. Not surprisingly, Ophthotech shares were up significantly (24.5%).

But there are still a couple of years to go before initial phase III data on Fovista will be available.

Label Expansion for Amgen's (Nasdaq:AMGN-Free Report)Vectibix: Amgen's colorectal cancer drug, Vectibix, can now be used for the first-line treatment of KRAS metastatic colorectal cancer in combination with Folfax chemo. Late-stage data showing that the addition of Vectibix to Folfax pushed up overall survival rates significantly (4.4 months) should ensure robust sales for Vectibix in this new setting. Vectibix delivered sales of $389 million last year.

Biogen's (Nasdaq:BIIB-Free Report)Plegridy Closer to EU Approval: Biogen, well known for its strong presence in the multiple sclerosis (MS) market, could see its experimental MS drug, Plegridy, gain EU approval shortly. The CHMP has issued a positive opinion. Plegridy is also under review in the U.S. where a response should be out in the second half of the year.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on ISIS - FREE

Get the full Report on PTCT - FREE

Get the full Report on OPHT - FREE

Get the full Report on AMGN - FREE

Get the full Report on BIIB - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
General and news information or questions:
Across the Midlands Information:
events@nebraska.tv
Comments: comments@nebraska.tv
News:
news@nebraska.tv
Phone: 308-743-2494
News Fax: 308-743-2660
All content © Copyright 2000 - 2014 WorldNow and NTV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.